VARONIS SYSTEMS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VARONIS SYSTEMS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $270.29M | Feb 12, 2019 |
| FY2018 | Dec 31, 2017 | $215.39M | Feb 12, 2019 |
| FY2018 | Dec 31, 2016 | $165.86M | Feb 12, 2019 |
| FY2017 | Dec 31, 2015 | $127.21M | Feb 13, 2018 |
| FY2016 | Dec 31, 2014 | $101.35M | Feb 9, 2017 |
| FY2015 | Dec 31, 2013 | $74.62M | Feb 12, 2016 |
| FY2014 | Dec 31, 2012 | $53.41M | Feb 19, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $491.56M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $457.10M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $427.41M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $403.80M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $330.74M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $248.43M | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $219.05M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $242.61M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $194.68M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $150.13M | Feb 12, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($129.32M) | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | ($95.77M) | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | ($100.92M) | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | ($124.52M) | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | ($116.86M) | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | ($94.01M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | ($78.76M) | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | ($28.58M) | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | ($13.84M) | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | ($14.19M) | Feb 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($146.51M) | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | ($117.65M) | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | ($117.22M) | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | ($121.23M) | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | ($98.69M) | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | ($78.42M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | ($75.99M) | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | ($29.14M) | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | ($13.42M) | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | ($12.00M) | Feb 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.81M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $196.77M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $183.84M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $177.88M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $137.88M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $99.36M | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $80.76M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $69.97M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $47.37M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $36.66M | Feb 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.43M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $115.20M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $59.42M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $11.87M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $7.18M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | ($5.84M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | ($10.68M) | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $23.55M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $16.35M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $7.35M | Feb 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.63M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $6.69M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $5.10M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $11.40M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $10.49M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $10.12M | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $25.39M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $9.58M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $5.31M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $3.83M | Feb 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $1.66B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $1.10B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.04B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $1.11B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $555.48M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $318.31M | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $284.98M | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $245.64M | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $181.84M | Feb 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $598.66M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $455.66M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $489.65M | Feb 4, 2026 |
| FY2025 | Dec 31, 2022 | $502.13M | Feb 4, 2026 |
| FY2024 | Dec 31, 2021 | $596.59M | Feb 6, 2025 |
| FY2023 | Dec 31, 2020 | $94.07M | Feb 6, 2024 |
| FY2022 | Dec 31, 2019 | $93.53M | Feb 7, 2023 |
| FY2021 | Dec 31, 2018 | $125.37M | Feb 8, 2022 |
| FY2020 | Dec 31, 2017 | $114.64M | Feb 9, 2021 |
| FY2019 | Dec 31, 2016 | $95.95M | Feb 11, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $135.28M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $23.14M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $23.14M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $23.14M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $23.14M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $23.14M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Feb 9, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($869.48M) | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | ($740.16M) | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | ($644.39M) | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | ($543.47M) | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | ($427.60M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | ($310.74M) | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | ($216.73M) | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | ($137.97M) | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | ($109.39M) | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | ($106.14M) | Feb 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.48M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $185.59M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $230.74M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $367.80M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $805.76M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $234.09M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $68.93M | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $48.71M | Feb 11, 2020 |
| FY2019 | Dec 31, 2017 | $56.69M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $48.32M | Feb 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 6, 2025 |
| FY2021 | Dec 31, 2021 | (1) | Feb 8, 2022 |
| FY2023 | Dec 31, 2021 | (1) | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Feb 8, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Feb 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 6, 2025 |
| FY2021 | Dec 31, 2021 | (1) | Feb 8, 2022 |
| FY2023 | Dec 31, 2021 | (1) | Feb 6, 2024 |
| FY2021 | Dec 31, 2020 | (1) | Feb 8, 2022 |
| FY2022 | Dec 31, 2020 | (1) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 117.55M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 112.55M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | 109.10M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | 107.67M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 107.51M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | 95.46M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | 30.58M | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | 29.58M | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | 28.15M | Feb 12, 2019 |
| FY2018 | Dec 31, 2016 | 26.82M | Feb 12, 2019 |